We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
151
Dyne Therapeutics
DYN
$4.94B
$220K 0.03%
23,063
-7,036
-23% -$77.5K
BCAX
152
Bicara Therapeutics
BCAX
$1.67B
$213K 0.03%
+22,875
New +$273K
KURA icon
153
Kura Oncology
KURA
$830M
$198K 0.03%
34,300
+9,300
+37% +$57K
DYN icon
154
CALL
Dyne Therapeutics
DYN
$4.94B
$190K 0.03%
+20,000
New +$220K
DAWN
155
DELISTED
Day One Biopharmaceuticals
DAWN
$182K 0.03%
28,023
– –
RXRX icon
156
Recursion Pharmaceuticals
RXRX
$1.68B
$177K 0.03%
35,000
+20,000
+133% +$98.3K
TRVI icon
157
Trevi Therapeutics
TRVI
$2.68B
$164K 0.03%
+30,000
New +$187K
CLBR
158
DELISTED
Colombier Acquisition Corp II
CLBR
$155K 0.02%
10,000
-8,513
-46% -$112K
AVXL icon
159
Anavex Life Sciences
AVXL
$291M
$150K 0.02%
16,221
– –
INZY
160
DELISTED
Inozyme Pharma
INZY
$149K 0.02%
37,161
-50,638
-58% -$125K
CLYM
161
Climb Bio
CLYM
$715M
$148K 0.02%
119,320
– –
DSGN icon
162
Design Therapeutics
DSGN
$849M
$143K 0.02%
+42,408
New +$159K
URGN icon
163
UroGen Pharma
URGN
$2.31B
$137K 0.02%
+10,000
New +$96K
PHGE icon
164
BiomX
PHGE
$1.91M
$135K 0.02%
15,768
– –
CLOV icon
165
Clover Health Investments
CLOV
$2.24B
$135K 0.02%
48,300
+20,000
+71% +$65.8K
AVTR icon
166
Avantor
AVTR
$9.1B
$135K 0.02%
+10,000
New +$137K
PCAPU
167
ProCap Acquisition Corp Unit
PCAPU
$212M
$114K 0.02%
+10,680
New +$118K
ALMS
168
Alumis Inc
ALMS
$3.43B
$113K 0.02%
+37,788
New +$178K
KALV
169
DELISTED
KalVista Pharmaceuticals
KALV
$113K 0.02%
10,000
-25,743
-72% -$315K
SLN
170
Silence Therapeutics
SLN
$530M
$108K 0.02%
18,643
– –
PMVP icon
171
PMV Pharmaceuticals
PMVP
$63.5M
$107K 0.02%
101,008
– –
TERN
172
DELISTED
Terns Pharmaceuticals
TERN
$106K 0.02%
+28,415
New +$88.7K
ENGN icon
173
enGene Therapeutics
ENGN
$119M
$101K 0.02%
27,787
+3,988
+17% +$15K
ACHV icon
174
Achieve Life Sciences
ACHV
$682M
$97.6K 0.02%
43,173
– –
OGN icon
175
Organon & Co
OGN
$3.56B
$96.8K 0.01%
10,000
– –
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.